Document Detail


Comparison of everolimus- and sirolimus-eluting stents in patients with long coronary artery lesions: a randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III) Trial.
MedLine Citation:
PMID:  22017935     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: This study compared everolimus-eluting stents (EES) and sirolimus-eluting stents (SES) for long coronary lesions.
BACKGROUND: Outcomes remain relatively unfavorable for stent-based coronary intervention of lesions with long diseased segments.
METHODS: This randomized, multicenter, prospective trial compared the use of long EES with SES in 450 patients with long (≥ 25 mm) native coronary lesions. The primary endpoint of the trial was in-segment late luminal loss at 9-month angiographic follow-up.
RESULTS: The EES and SES groups had similar baseline characteristics. Lesion length was 34.0 ± 15.4 mm in the EES group and 34.3 ± 13.5 mm in the SES group (p = 0.85). Nine-month angiographic follow-up was performed in 80% of the EES group and 81% of the SES group (p = 0.69). In-segment late loss as the primary study endpoint was significantly larger in the EES group than in the SES group (0.17 ± 0.41 mm vs. 0.09 ± 0.30 mm, p for noninferiority = 0.96, p for superiority = 0.04). The in-segment binary restenosis rate was also higher in the EES group than in the SES group (7.3% vs. 2.7%, p = 0.046). However, in-stent late loss (0.22 ± 0.43 mm vs. 0.18 ± 0.28 mm, p = 0.29) and in-stent binary restenosis rate (3.9% vs. 2.7%, p = 0.53) were similar among the 2 groups. The incidence of any clinical outcomes (death, myocardial infarction, stent thrombosis, target lesion revascularization, and composite outcomes) was not statistically different between the 2 groups.
CONCLUSIONS: For patients with long native coronary artery disease, EES implantation was associated with greater angiographic in-segment late loss and higher rates of in-segment restenosis compared with SES implantation. However, clinical outcomes were both excellent and not statistically different.
Authors:
Duk-Woo Park; Young-Hak Kim; Hae-Geun Song; Jung-Min Ahn; Won-Jang Kim; Jong-Young Lee; Soo-Jin Kang; Seung-Whan Lee; Cheol Whan Lee; Seong-Wook Park; Sung-Cheol Yun; Ki-Bae Seung; Tae-Hyun Yang; Sang-Gon Lee; Jae-Hwan Lee; In-Whan Seong; Sang-Sig Cheong; Bong-Ki Lee; Nae-Hee Lee; Se-Whan Lee; Seung-Wook Lee; Keun Lee; Hyun-Sook Kim; Doo-Soo Jeon; Min-Kyu Kim; Deuk-Young Nah; Seung-Jea Tahk; Seung-Jung Park
Related Documents :
7489265 - Short-term treatment outcome study for the management of temporomandibular joint closed...
21990185 - A prospective study on quality of life and functional outcome in children and adolescen...
3183675 - Long-term results of silicone trapezial implant arthroplasty.
21810815 - Use of the hardman index in predicting mortality in endovascular repair of ruptured abd...
9010185 - Total hip arthroplasty with cement for juvenile rheumatoid arthritis. results at a mini...
16639475 - Trends in five-year survival of patients discharged after acute myocardial infarction.
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  JACC. Cardiovascular interventions     Volume:  4     ISSN:  1876-7605     ISO Abbreviation:  JACC Cardiovasc Interv     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-10-24     Completed Date:  2012-02-27     Revised Date:  2014-09-05    
Medline Journal Info:
Nlm Unique ID:  101467004     Medline TA:  JACC Cardiovasc Interv     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1096-103     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT01078038
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angioplasty, Balloon, Coronary
Coronary Angiography
Coronary Restenosis / drug therapy*,  mortality,  therapy
Coronary Vessels / pathology*
Drug-Eluting Stents*
Female
Humans
Immunosuppressive Agents / therapeutic use*
Kaplan-Meier Estimate
Male
Middle Aged
Recurrence
Sirolimus / analogs & derivatives*,  therapeutic use*
Statistics as Topic
Time Factors
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents; 159351-69-6/everolimus; W36ZG6FT64/Sirolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical utility of regadenoson for assessing fractional flow reserve.
Next Document:  Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary s...